In 2006, the US Food and Drug Administration (FDA) approved the first vaccine for
prevention of cervical cancer based on the molecular biology of the disease. Gardasil® …

Opinion statement In the United States, there are 11,150 cases and 3670 deaths projected
due to invasive cervical cancer for 2007. Approximately 500,000 new cases and 274,000 …

The challenges of the journey from target identification through development of a
prophylactic quadrivalent human papillomavirus (HPV) vaccine have been met in Gardasil® …

Gardasil, a vaccine against human papillomavirus (HPV), recently became available in the
United States for use in girls and women 9 to 26 years of age. A second HPV vaccine …

Objectives To review the epidemiology and natural history of human papillomavirus (HPV),
summarize relevant clinical trials of the prophylactic HPV vaccines, and describe the …

The discovery of the association between infection by the human papillomavirus (HPV) and
the development of cervical cancer has been the foundation for establishing HPV as the …

Abstract In October 2009, the Advisory Committee on Immunization Practices (ACIP)
approved a newly licensed vaccine, Cervarix®, directed against human papillomavirus …

Since the discovery of the causal association between human papillomavirus (HPV) and
cervical cancer, efforts to develop an effective prophylactic vaccine to prevent high-risk HPV …

Human papillomaviruses (HPVs) are one of the most common sexually transmitted
infections and remains a public health problem worldwide. There is strong evidence that …

Human papillomavirus infection, the most common sexually transmitted infection in the
United States, is associated with the development of cervical cancer. The new human …